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A combination of chemical genetic and biochemical
assays was applied to investigate the mechanism of
action of the anticancer drug 5-fluorouracil (5-FU),
against Mycobacterium tuberculosis (Mtb). 5-FU
resistance was associated with mutations in upp
or pyrR. Upp-catalyzed conversion of 5-FU to
FUMP was shown to constitute the first step in the
mechanism of action, and resistance conferred by
nonsynonymous SNPs in pyrR shown to be due to
derepression of the pyr operon and rescue from
the toxic effects of FUMP and downstream
antimetabolites through de novo production of
UMP. 5-FU-derived metabolites identified in Mtb
were consistent with the observed incorporation of
5-FU into RNA and DNA and the reduced amount
of mycolyl arabinogalactan peptidoglycan in 5-FU-
treated cells. Conditional depletion of the essential
thymidylate synthase ThyX resulted in modest
hypersensitivity to 5-FU, implicating inhibition of
ThyX by fluorodeoxyuridylate as a further compo-
nent of the mechanism of antimycobacterial action
of this drug.
INTRODUCTION
Fluoropyrimidines were first described in 1957 as anticancer
agents that also exhibited profound inhibitory effects on the
growth and viability of various microorganisms (Heidelberger
et al., 1957). The pyrimidine analog 5-fluorouracil (5-FU) and
its derivatives demonstrate clinical efficacy in a wide variety of
cancers (Longley et al., 2003). Although 5-FU is arguably the
most successful drug approved to date for the treatment of
cancer, its use as an antibacterial agent has not been exten-
sively explored. The first study of the antimicrobial toxicity of
5-FU was performed in Escherichia coli and found that its majorChemistry & Biology 22,inhibitory effect results from the intracellular conversion to
fluorodeoxyuridylate (FdUMP), which prevents the reductive
methylation of deoxyuridine 50-monophosphate (dUMP) by in-
hibiting the enzyme thymidylate synthase (TS) (Cohen et al.,
1958). The cessation of DNA synthesis resulting from dTMP
starvation was thought to result in ‘‘thymineless death.’’ In
another study, E. coli K-12 cells treated with 5-FU were found
to exhibit increased sensitivity to heat and mechanical stress
due to the osmotic imbalance caused by accumulation of cell
wall precursors (Tomasz and Borek, 1960). It was subsequently
shown that exogenous uracil or uridine, but not thymine or
thymidine, could protect against the bactericidal action of
5-FU, consistent with perturbation of cell wall biosynthesis as
a mechanism for 5-FU toxicity (Tomasz and Borek, 1962).
5-FU was also shown to partially inhibit cell-wall mucopeptide
synthesis in Staphylococcus aureus, with the inhibition similarly
reversible by uracil or uridine (Rogers and Perkins, 1960), and in
Pneumococcus, derivatives of 5-FU caused distinct inhibitory
effects and differed in their metabolic fates (Bean and Tomasz,
1971). In 1979, 5-FU was shown to exhibit activity against
Mycobacterium tuberculosis (Mtb) and M. intracellulare (Tsuka-
mura, 1979), leading the author to propose the use of 5-FU as a
potentially effective agent against M. intracellulare strains that
were resistant to all antitubercular agents available at the
time. Tsukamura also observed two 5-FU-resistant phenotypes
in Mtb, but despite early interest in 5-FU, its mechanism of
action and potential as an antitubercular agent have not been
investigated.
The magnitude of the global health problem of tuberculosis
(TB) has underscored the urgent need for new drugs to treat
drug-susceptible and drug-resistant forms of the disease
(Zumla et al., 2013b). Major efforts over the past decade have
led to the establishment of an impressive global TB drug pipe-
line, which contains a number of new drugs and drug combina-
tions that are currently in clinical development (Zumla et al.,
2013a; Zumla et al., 2014). Phenotypic approaches that harness
the power of postgenomic technologies are playing a pivotal
role in populating the front end of the pipeline with compounds
that are active against Mtb cultured under various conditions
and display novel mechanisms of action (Lechartier et al.,63–75, January 22, 2015 ª2015 Elsevier Ltd All rights reserved 63
Table 1. Susceptibility of Mtb Strains to 5-Fluoropyrimidines
Strain
MIC90 (mM)
a
5-FU Carmofur FUrd FdUrd
Mtb
H37Rv 3.1 3.1 800 400
H37Ra 4 – – –
MTBSRM1 400 400 >1,600 >1,600
MTBSRM1::upp 3.1 – – –
MTBSRM1::pyrR 400 – – –
MTBSRM2 >1,600 >1,600 >1,600 >1,600
MTBSRM2::pyrR 12.5 – – –
MTBSRM2::upp >1,600 – – –
MTBSRM3 400 400 >1,600 >1,600
MTBSRM4 >1,600 >1,600 >1,600 >1,600
MTBSRM5 >1,600 >1,600 >1,600 >1,600
MTBSRM6 >1,600 >1,600 >1,600 >1,600
MTBSRM7 400 400 >1,600 >1,600
MTBSRM8 >1,600 >1,600 >1,600 >1,600
MTBSRM9 >1,600 >1,600 >1,600 >1,600
MTBSRM10 >1,600 >1,600 >1,600 >1,600
upp::Tn 400 – – –
upp::Tn attB::upp 3.1 – – –
See also Figure S1.
aDetermined by broth microdilution using the Alamar Blue assay (with vi-
sual readout) described in Experimental Procedures for all strains other
than H37Ra, for which the MIC was determined by visual examination
of growth (pellet size) after 5 days in static culture.
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Figure 1. Proposed Pathway for 5-FU Metabolism and Targets of
5-FU Metabolites in Mtb
Cmk, CMP kinase (Rv1712); DeoA, thymidine phosphorylase (Rv3314c); Dut,
dUTPase (Rv2697c); Ndk, nucleoside disphosphate kinase (Rv2445c); PyrH,
UMP kinase (Rv2883c); PyrR, pyrimidine operon attenuation protein/uracil
phosphoribosyltransferase (Rv1379); RNR, ribonucleotide reductase; Tmk,
TMP kinase (Rv3247c); Upp, uracil phosphoribosyltransferase (Rv3309c).
Dashed arrows represent steps for which the canonical enzymes are absent in
Mtb (Villela et al., 2011; Warner et al., 2014).
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typic screening of compound libraries for whole-cell activity
against Mtb have also provided an important resource in the
form of chemical probes to identify new drug targets and
explore metabolic pathways in this pathogen (Goldman and
Laughon, 2009; Grant et al., 2013; Ioerger et al., 2013; Lechart-
ier et al., 2014; Stanley et al., 2012).
In this study, we used a combination of postgenomic tools and
classical biochemistry to elucidate the mechanisms of resis-
tance and action of 5-FU in Mtb. We discuss our findings in the
context of pyrimidine metabolism as a potential target for antitu-
bercular drug discovery.
RESULTS
5-FU Has Bactericidal Activity against Mtb
5-FU was shown to have activity against Mtb, with a 90% mini-
mum inhibitory concentration (MIC90) value of 3.1 mM, as deter-
mined by broth microdilution assay (Table 1). The effect of 5-FU
on Mtb viability was assessed by plating 5-FU-treated cultures
and scoring for colony-forming units. This compound showed
time- and concentration-dependent kill, with a 99% minimum
bactericidal concentration value of 8 mM over 8 days for Mtb
(Figure S1 available online). The 5-FU analog carmofur (1-hexyl-
carbamoyl-5-FU) was as active as 5-FU against Mtb, whereas
5-fluorouridine (FUrd) and 5-fluorodeoxyuridine (FdUrd) showed
very poor activity (Table 1).64 Chemistry & Biology 22, 63–75, January 22, 2015 ª2015 ElsevierResistance to 5-FU in Mtb Is Conferred by Mutations in
upp or pyrR
To investigate the mechanism of antimycobacterial action of
5-FU, we raised spontaneous resistant mutants of Mtb against
5-FU by plating logarithmic-phase cultures on Middlebrook
7H10 agar supplemented with 5-FU at 53MIC90. Mutants arose
at a frequency of 107. Ten individual colonies were picked,
grown in 7H9 media supplemented with 5-FU at the MIC90,
and tested for 5-FU susceptibility. The 5-FUR mutants of Mtb
fell into two classes, which differed in the level of resistance,
with one being markedly more resistant than the other (MIC90
> 1,600 mM versus 400 mM; Table 1). Both classes of mutants
showed cross-resistance to FUrd and FdUrd (>1,600 mM; Table
1), suggesting that these compounds exert their weak inhibitory
effects through metabolism to 5-FU, presumably via thymidine
phosphorylase (DeoA) in the former case and a noncanonical uri-
dine phosphorylase in the latter. However, 5-FUR mutants from
both classes showed no cross-resistance to standard TB drugs
(rifampicin, isoniazid, ethambutol, p-aminosalicylic acid, strep-
tomycin, and levofloxacin).
Potential pathways for 5-FU metabolism in Mtb were consid-
ered by analyzing the complement of genes involved in pyrimi-
dine salvage (Figure 1) (Villela et al., 2011; Warner et al., 2014).
This analysis suggested that the most likely route for metabolism
of 5-FU would be via conversion to FUMP; other pathways were
considered less likely to operate owing to the absence of canon-
ical thymidine kinase, uridine phosphorylase, and uridine kinase
homologs in Mtb (Davis et al., 2009; Villela et al., 2011). Mtb
has two putative uracil phosphoribosyltransferase (UPRTase)
enzymes that could potentially metabolize 5-FU to FUMP: the
canonical Upp (Rv3309c) and the pyrimidine regulator PyrRLtd All rights reserved
Table 2. Genotypes of Spontaneous 5-FUR Mutants of Mtb
Strain upp pyrR
MTBSRM1 Da74a –
MTBSRM2 – Asp91Asn
MTBSRM3 Da74 –
MTBSRM4 – Leu180Pro
MTBSRM5 – Leu62Pro
MTBSRM6 – Leu180Pro
MTBSRM7 Da74 –
MTBSRM8 – Gly125Val
MTBSRM9 – Arg126Cys
MTBSRM10 – Arg126Cys
See also Figure S7.
aDeletion of adenine at position 74 of the gene.
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analogy with Bacillus caldolyticus PyrR (Chander et al., 2005).
Sequence analysis of upp and pyrR in the 5-FUR mutants
confirmed that resistance was associated with mutations in
either of these genes (Table 2). In a parallel approach, 5-FURmu-
tants were also selected by transposon (Tn) mutagenesis of Mtb
H37Rv and plating on agar containing kanamycin (to select for Tn
insertion) and 5-FU at 3.1 mM (13MIC90). Twenty-three mutants
were identified, and all showed a 125-fold increase in the MIC90
for 5-FU. The Tn insertion site mapped to upp in 22/23 cases
and to Rv3268 in the remaining mutant; however, this mutant
also carried a nonsynonymous SNP in upp, resulting in a
Asp129Gly substitution. Thus, in all cases, the loss of Upp func-
tion appeared to account for the 5-FU resistance phenotype. No
Tn insertions were identified in pyrR. This gene is the first in an
operon of genes that are involved in de novo pyrimidine biosyn-
thesis (Figure 2A) and are essential for growth of Mtb in vitro
(Sassetti et al., 2003). By exerting polar effects on these genes,
Tn insertions in pyrR would be lethal.
Delivery of a wild-type copy of Mtb pyrR expressed from its
native promoter into the chromosome of MTBSRM2, a represen-
tative 5-FUR mutant carrying a mutation in pyrR (Table 2), via an
integration vector restored 5-FU susceptibility (Table 1). Simi-
larly, integration of Mtb upp expressed from its own promoter
fully restored the 5-FU susceptibility of MTBSRM1, a 5-FUR
mutant carrying a frameshift mutation in upp as well as a Tn
mutant carrying an insertion in upp (Table 2), to the level of the
wild-type (MIC90 = 3.1 mM) (Table 1). In contrast, complementa-
tion with the noncognate genes had no effect on the 5-FU sus-
ceptibility of the resistant mutants (Table 1). These results
confirmed the association between the 5-FUR phenotype of
MTBSRM2 with an alteration in PyrR function, and that of
MTBSRM1 and upp::Tn with a loss of Upp function, respectively.
Comparison of the growth kinetics of MTBSRM1 andMTBSRM2
with the parental wild-type confirmed that the 5-FUR-conferring
mutations identified in upp or pyrR had no effect on growth in
axenic culture (data not shown).Uracil Rescues Mtb from 5-FU Toxicity
The mechanism of 5-FU resistance elucidated in Mtb suggested
that this prodrug exploits the pyrimidine salvage pathway for itsChemistry & Biology 22,mechanism of action. We therefore investigated whether pyrim-
idine supplements could rescue Mtb from 5-FU toxicity. Uracil
supplementation showed dose-dependent rescue of wild-type
Mtb from 5-FU inhibition, raising the MIC90 of 5-FU from
3.1 mM to 400 mM when added over a concentration range of
0 to 1,000 mM (Figure S1B). In contrast, uracil supplementation
had no effect on the 5-FU susceptibility of MTBSRM1 or
MTBSRM2 over this range (data not shown). Uridine had a minor
effect on the 5-FU susceptibility of wild-type Mtb, increasing the
5-FUMIC90 from 3.1 to 12.5 mMwhen added at 1,000 mM, but no
effect on the susceptibility of MTBSRM1 (data not shown). More-
over, neither thymine nor thymidine supplementation affected
the 5-FU susceptibility of wild-type Mtb when added at concen-
trations up to 1,000 mM (data not shown).
PyrR Mutations Conferring 5-FU Resistance Result in
Overproduction of pyr Operon-Encoded Proteins in Mtb
In mycobacteria, most, but not all, of the enzymes in the de novo
pyrimidine biosynthesis pathway are encoded by genes in the
pyr operon (Figure 2A). Others have shown that in Mycobacte-
rium smegmatis, exogenous uracil represses the pyr operon
via a translational repression mechanism involving uridine nucle-
otide binding to PyrR, and that deletion of this regulator leads to
increased production of UMP (Fields and Switzer, 2007). To
investigate the effect of 5-FU resistance on the expression of
pyrR and genes encoding the pyrimidine biosynthesis enzymes,
PyrB, PyrC, CarA, CarB, and PyrE, we used droplet digital PCR
(ddPCR) to measure the absolute concentration of each tran-
script relative to the house-keeping gene, sigA, in the wild-
type, MTBSRM1 and MTBSRM2 strains in log phase cells. The
levels of pyrR, pyrB, pyrC, carA, carB, and pyrF transcript were
all significantly elevated in MTBSRM2 relative to wild-type (p <
0.0001). pyrB, pyrC, carA, and pyrF transcript levels were also
elevated in MTBSRM1, albeit to a lesser extent than in
MTBSRM2, while pyrR and carB transcript levels were moder-
ately repressed (Figure 2B). However, the level of pyrE transcript
was indistinguishable from wild-type in both mutant strains, dis-
tinguishing this gene from those in the pyr operon.
The same samples were then analyzed bymeans of label-free,
quantitative proteomics to quantify the abundance of the pyr
operon encoded proteins, PyrR, PyrB, PyrC, CarA, CarB, and
PyrF, along with the controls, PyrE and SigA (Figure 2C). The
normalized intensities of all proteins in MTBSRM1 were indistin-
guishable from the wild-type strain with the exception of CarA,
which was 2.4-fold higher in the mutant strain (p < 0.001). In
contrast, the levels of all six pyr operon-encoded proteins were
significantly elevated in MTBSRM2 compared to the wild-type
(p < 0.001), whereas PyrE and SigA levels were indistinguishable
from wild-type. Importantly, complementation of MTBSRM2
restored PyrB, PyrC and CarB levels to wild-type, and also
reduced the levels of CarA andPyrF. On the basis of these obser-
vations, we extended the proteomic analysis to include four
other 5-FUR mutants, MTBSRM4, MTBSRM5, MTBSRM8, and
MTBSRM9, which harbor different mutations in pyrR (Figure S2).
The levels of PyrB, PyrC, CarA, CarB, and PyrF in mid log phase
cultures were significantly higher (up to 9 fold) in all four 5-FUR
strains carrying nonsynonymous SNPs in pyrR (p < 0.001),
whereas SigA and PyrE levels were indistinguishable from
wild-type (p > 0.05) (Figure S2). PyrR levels were also63–75, January 22, 2015 ª2015 Elsevier Ltd All rights reserved 65
AB
C
Figure 2. Proteins Encoded by the pyr
Operon Are Induced at the mRNA and Pro-
tein Levels in MTBSRM2
(A) Genetic organization of the pyr operon encod-
ing enzymes of the de novo pyrimidine biosyn-
thesis pathway in Mtb. The biochemical functions
of the genes in the pyr operon are as shown, and
the genes (and their encoded proteins) included in
the expression analysis are shaded in gray.
(B) ddPCR analysis showing log2-fold change in
expression of sigA-normalized genes in MTBSRM1
and MTBSRM2 relative to H37Rv. RNA was iso-
lated from log phase cells (OD600 = 0.5), and the
concentration of each transcriptwasdetermined by
ddPCR, as described in Experimental Procedures.
The fold change in sigA-normalized transcript was
calculated relative to the untreated control. All the
data generated by QuantaSoft software included
the 95% confidence interval. Each sample was
analyzed in triplicate on at least three independent
biological replicates to give nine data sets for
analysis. The results aremean ± SD. Values labeled
with asterisks are statistically significantly different,
as determined using one-way ANOVA: *p < 0.05,
**p < 0.005, ***p < 0.0005, ****p < 0.0001; ns,
p > 0.05.
(C) Label-free quantitative MS analysis of 5-FUR
mutants MTBSRM1 and MTBSRM2 and of com-
plemented strain MTBSRM2::pyrR showing Log2
fold change in intensities of tryptic peptides
derived from the pyr operon encoded proteins,
PyrR, PyrB, PyrC, CarA, CarB, and PyrF, and the
controls, PyrE, and SigA, relative to H37Rv. The
data represent the mean and SE from three inde-
pendent biological replicates. Asterisks represent
statistically significant differences, analyzed using
two-way ANOVA: **p < 0.01; ***p < 0.001; ns,
p > 0.05.
See also Figure S2.
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but not in MTBSRM4 and MTBSRM5. Together, these data sug-
gested that all five pyrRmutations identified in 5-FUR mutants of
Mtb functionally impair PyrR and result in increased production
of pyr operon-encoded proteins.
Mtb Upp Has Significantly Higher UPRTase Activity than
PyrR and Utilizes 5-FU as a Substrate
To assess which enzyme provides the major UPRTase activity
in Mtb, we expressed and purified Upp and PyrR as N-terminal
His-tagged recombinants in E. coli and compared their abilities
to catalyze the conversion of uracil and 5-FU to UMP and 5-
FUMP, respectively, by Michaelis-Menten kinetic analyses in
the presence of a saturating concentration of phosphoribosyl py-66 Chemistry & Biology 22, 63–75, January 22, 2015 ª2015 Elsevier Ltd All rights reservedrophosphate (Figure S3; Table S1). Both
proteins displayed UPRTase activity on
both substrates, with the kinetic con-
stants for Upp using uracil as substrate
being comparable with those reported
by others (Villela et al., 2013). Upp
showed higher Vmax and lower Km values
than PyrR for both uracil and 5-FU, sug-gesting that Upp is likely to provide the major UPRTase activity
in Mtb.
Trace Labeling Reveals Complex Metabolism of
5-FU in Mtb
The evidence provided above established that metabolism to
FUMP constitutes the first step in the mechanism of action of
5-FU. To investigate the subsequent metabolic fate of 5-FU,
we followed further enzymatic conversions of this molecule by
trace labeling a culture of Mtb H37Ra with 5-F[14C]U over a
48 hr period. The radiolabeled metabolites were extracted from
cell pellets with formic acid, a method that was found to give
reproducible yields of nucleotides from bacteria (Bochner and
Ames, 1982). We observed rapid uptake of 5-F[14C]U by Mtb
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Figure 3. Characterization and Fate of 5-FU Metabolites in Mtb
(A) TLC analysis of nucleotides extracted from 5F-[14C]-U treated Mtb H37Ra cells. Five microliter aliquots of the formic acid extracts from the time-course
experiment were loaded on a PEI cellulose TLC plate, chromatographed in 0.9 M guanidine hydrochloride, and exposed to X-ray film at 80C for 10 days. Acid
phosphatase treatment of the 12 hr sample was carried out as described in Experimental Procedures. See also Table S2.
(B) Analysis of 5-F[14C]U-labeled nucleic acids in Mtb H37Ra. RNA was isolated from 10 ml culture of Mtb H37Ra (OD600 = 1) treated with 5-F[
14C]U for 24 hr,
separated on a 1%agarose gel (left) and transferred to Hybond-N+membrane, whichwas exposed to X-ray film for 30 days at80C (right, northern blot). Lane 1,
200 ng RNA (680 dpm); lane 2, DNA markers; lane 3; 400 ng RNA (1,360 dpm). DNA was extracted from two 10 ml cultures of Mtb H37Ra (culture 1, OD600 = 0.2;
culture 2, OD600 = 0.4) treated with 5-F[
14C]U for 24 hr, separated on 0.7%agarose gel (left) and transferred to a Hybond-N+membrane, which was exposed to X-
ray film for 13 days at80C (right, Southern blot). Lane 4, 350 ng DNA from culture 1 (2,855 dpm); lane 5, DNAmarkers; lane 6, 350 ng DNA from culture 2 (2,624
dpm).
(C) Transcriptional response of radA and recA to treatment of Mtb H37Rv with 5-FU, mitomycin C (MMC), or ofloxacin (OFX). A culture of wild-type Mtb (H37Rv)
was treated with drug at a concentration of 10 3 MIC90 (30 mM 5-FU; MMC [0.6 mM]; OFX [16.6 mM]) for 6 hr. The concentrations of radA and recA transcript
relative to sigA were determined by ddPCR analysis of RNA, as described in Experimental Procedures, and the fold change in sigA-normalized transcript
calculated relative to the untreated control. All data generated by QuantaSoft software included the 95% confidence interval. Each sample was analyzed in
triplicate on three separate biological replicates to give nine data sets for analysis. The results are mean ± SD. Values labeled with asterisks are statistically
significant, as determined using one-way ANOVA: ****p < 0.0001.
(D) HPLC analysis of formic acid extracts of Mtb H37Rv. Aliquots (5 ml) of the extracts obtained from control and 5-FU-treated cultures were analyzed by HPLC
using a BioBasic AX anion exchange column and a gradient of 0.5 to 750 mM KH2PO4 (pH 3.2). The peaks are labeled according to elution of the corresponding
standards.
See also Table S3 and Figures S4 and S5.
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plateau after 12 hr (Table S2). The extracts enriched in nucleo-
tides were separated by thin-layer chromatography (TLC) (Boch-
ner and Ames, 1982). Subsequent autoradiography of the TLC
plate revealed a distinct pattern of at least six prominent spots
(Figure 3A). One of these comigrated with a 5-FUMP standard
produced from 5-FU by recombinant Mtb Upp, as described
earlier. This standard migrated differently from the natural
metabolite UMP. Similarly, there was a shift in Rf values of the
radioactive signals compared with other standards, namely,
UTP, UDP, UDP-GlcNAc, and UDP-Galp (data not shown). ToChemistry & Biology 22,further characterize the other radiolabeled metabolites, we di-
gested the formic acid extract and cold standards with acid
phosphatase and separated the mixtures on TLC. This enzyme
completely removed phosphates from UTP and UDP, whereas
UMP and the sugar nucleotides were relatively resistant to this
treatment. On the basis of these observations, we concluded
that the slowest migrating radiolabeled compounds were 5-F
[14C]UTP and 5-F[14C]UDP, since they phenocopied UTP and
UDP by disappearing after acid phosphatase treatment (Fig-
ure 3A). We surmised that the three radiolabeled metabolites
migrating in the region of UDP-based sugar nucleotides63–75, January 22, 2015 ª2015 Elsevier Ltd All rights reserved 67
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Mechanism of Antimycobacterial Action of 5-FUstandards (UDP-GlcNAc, UDP-Gal) at the solvent front likely
represent fluorinated versions of these molecules.
5-FU Is Incorporated into RNA and DNA and Triggers
Genotoxic Stress in Mtb
The identification of 5-F[14C]UTP in nucleotide extracts of 5-F
[14C]U-treated Mtb H37Ra prompted us to examine the incorpo-
ration of radiolabel from 5-F[14C]U into nucleic acids. We moni-
tored radiolabeling of RNA or DNA following a 24 hr treatment
of exponentially growing Mtb H37Ra cultures with 0.2 mCi/ml
5-F[14C]U, corresponding to a concentration of 3.64 mM, which
is close to the MIC90 of 5-FU. Culture aliquots were harvested
and subjected to RNA or DNA isolation. The nucleic acids were
separated by agarose gel electrophoresis and visualized by
ethidium bromide staining before being transferred to Hybond-
N+ membranes. The profiles of RNA and DNA on the gels
matched the autoradiography signals from the northern and
Southern blots, respectively, confirming that 5-FU is metabo-
lized to FUTP and FdUTP in Mtb and incorporated into RNA
and DNA (Figure 3B).
To assess whether the incorporation of 5-FU into DNA triggers
a genotoxic stress response, we examined the effect of 5-FU
treatment on expression of the DNA-damage-responsive genes
recA and radA (Boshoff et al., 2003) in Mtb H37Rv by ddPCR.
Both genes were significantly upregulated by 5-FU at a concen-
tration of 30 mM (10 3 MIC90) (p % 0.0001), albeit to a lesser
extent than in cells treated with either mitomycin C or ofloxacin
(Figure 3C).
5-FU Inhibits Cell Wall Biosynthesis in Mtb
The putative identification of 5-FU-containing sugar nucleotides
by trace metabolite labeling suggested that 5-FU treatment
might affect cell wall biosynthesis in Mtb. To test this, we in-
vestigated the effect of 5-FU treatment on the cell wall by
biochemical analysis of themycobacterial mycolyl arabinogalac-
tan peptidoglycan (mAGP) complex. Parallel cultures of Mtb
H37Rv were either treated with 4 mM 5-FU for 6 days or left un-
treated. Cells harvested from both cultures were extracted with
10% formic acid and the remaining pellets were heat-sterilized.
Both the formic acid extracts and the cell pellets were lyophi-
lized, and the extracts were redissolved in water (10 ml/mg dry
cell weight). These were then analyzed by high-performance
liquid chromatography (HPLC) under conditions that allowed
separation of uracil-containing ribonucleotides and sugar nucle-
otides involved in biosynthesis of the mAGP complex. The HPLC
profiles revealed an increase in peak areas corresponding to the
retention times of UMP, UDP, UDP-GlcNAc, UDP-Galp, and
UDP-MurNAc-pentapeptide standards in the sample from 5-
FU-treatedMtb compared with the untreated control (Figure 3D).
To determine whether the increase reflected an accumulation
of the natural uracil-containing metabolites due to inhibition of
the pathways requiring these compounds or was caused by
buildup of 5-FU-containing counterparts of these metabolites
that coincidentally comigrate with the natural compounds, we
collected the individual peaks and attempted to analyze them
by mass spectrometry (MS). However, the presence of potas-
sium dihydrogen phosphate used for elution during the HPLC
separation was not compatible with MS detection, and chang-
ing the elution solvent to ammonium acetate, which would allow68 Chemistry & Biology 22, 63–75, January 22, 2015 ª2015 Elsevierits removal by lyophilization, compromised the separation. We
therefore coinjected the formic acid extract from 5-FU-treated
Mtb H37Rv with that prepared from 5-F[14C]U-treated Mtb
H37Ra and separated the extracts on HPLC. The fractions cor-
responding to the individual peaks, and regions between them,
were collected and their radioactivity quantified by liquid scintil-
lation counting. Eighty-nine percent of the radioactivity loaded
onto the HPLC was recovered in the peaks comigrating with
the UMP, UDP, UTP, UDP-GlcNAc, UDP-Galp, and UDP-Mur-
NAc-pentapeptide standards, suggesting that in this HPLC
system, the fluorinated and natural metabolites do not sepa-
rate (Figure S4). This was further confirmed by the observation
that the retention time of 5-FUMP, the only fluorinated standard
available, corresponded precisely to that of UMP. Therefore, in
addition to incorporating into ribonucleotides, 5-FU also incor-
porates into major sugar nucleotides involved in synthesis of
mycobacterial arabinogalactan (UDP-GlcNAc and UDP-Galp)
and peptidoglycan (UDP-GlcNAc and UDP-MurNAc-pentapep-
tide). As a result, 5-FU treated cells produced approximately
30% less mAGP, with a considerably lower content of peptido-
glycan (Table S3), confirming that this drug impairs production
of the mAGP complex and also affects its structure and
composition.
The biochemical evidence for inhibition of cell wall biosyn-
thesis was further reinforced by transcriptional analysis which
revealed significant 5-FU-mediated upregulation of the cell-
wall-stress-responsive genes, iniA and iniB in Mtb H37Rv (p <
0.0001), albeit to a lesser extent than in controls treated with
isoniazid or ethambutol (Figure S5).
Conditional Depletion of ThyX and NrdF2 Confers
Moderate Hypersensitization of Mtb to 5-FU
Biochemical studies have shown that FdUMP is a potent inhibi-
tor of both TS enzymes in Mtb, ThyA and ThyX (Hunter et al.,
2008). Because FUMP could potentially be metabolized to
FdUMP through the sequential action of UMP kinase (PyrH),
ribonucleotide reductase (NrdEF2), nucleoside diphosphate ki-
nase (Ndk), and dUTPase (Dut) (Figure 1), we postulated that
ThyX, the TS enzyme essential for Mtb growth in vitro (Fivian-
Hughes et al., 2012), might be an additional cellular target for
5-FU. To test this, we asked whether ThyX depletion confers hy-
persensitivity to 5-FU. Conditional ThyX mutants were con-
structed as previously described (Abrahams et al., 2012). Briefly,
the thyX gene was placed under the control of the anhydrotetra-
cycline (ATc)-regulated promoter-operator element, Pmyc1tetO
(Ehrt et al., 2005) via single-crossover (SCO) homologous recom-
bination, following which a vector carrying either the forward
(TetR) or reverse tetracycline repressor (rev-TetR) was intro-
duced to generate mutants in the Tet-ON and Tet-OFF con-
figurations, respectively. The thyX Tet-OFF and thyX Tet-ON
mutants showed ATc-dependent growth on agar (Figure 4A)
and in liquid culture (Figures 4B and 4C and data not shown).
The association between ATc-mediated transcriptional silencing
of thyX and growth impairment was confirmed by western blot
analysis which showed specific, time-dependent depletion of
ThyX in the thyX Tet-OFF strain, resulting in almost complete
disappearance of this protein at day 5 (Figure 4D). In contrast,
ThyX levels in H37Rv and thyX-SCO were unaffected by ATc
treatment over this time course.Ltd All rights reserved
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Figure 4. ATc Dose-Dependent Growth
of Conditional ThyX Knockdown Mutants
of Mtb
(A) Growth on 7H10 agar. Strains were grown to
mid-log phase and equivalent numbers of cells
spotted on media containing ATc at the indicated
concentrations.
(B and C) Growth of thyX Tet-ON (B) and thyX Tet-
OFF (C) in Middlebrook 7H9 medium was supple-
mented with ATc at the indicated concentrations.
The parental wild-type (H37Rv) and thyX-SCO
strains were included as controls. Data are from a
representative experiment performed in duplicate.
The numbers in parentheses represent the con-
centration of ATc (ng/ml).
(D) ATc-dependent depletion of ThyX in thyX Tet-
OFF confirmed by western blot analysis. Strains
cultured in Middlebrook 7H9 broth and either left
untreated (-) or exposed to ATc (500 ng/ml) (+) for
the indicated length of time. Western blotting was
carried out as described in Experimental Pro-
cedures, probing with antibodies against ThyX. As
a control, blots were probed with antibodies
against Wag31.
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bility was assessed using a checkerboard assay (Figure 5A). The
thyX-SCO strain showed a 2-fold lower MIC90 for 5-FU than
H37Rv (MIC90 = 1.56 versus 3.1 mM). Progressive ATc-induced
depletion of ThyX resulted in a further increase in 5-FU suscep-
tibility of thyX Tet-OFF (MIC90% 0.19 mM at 15.6 ng/ml ATc and
MIC90% 0.39 mM at 7.8 ng/ml ATc). In contrast, transcriptional
silencing of thyX had no effect on the MICs of isoniazid, etham-
butol, p-aminosalicylic acid, streptomycin, and levofloxacin
(data not shown). This argued against generalized hypersensitiv-
ity to antimycobacterials with different mechanisms of action
and suggested that among the drugs tested, hypersensitivity
conferred by ThyX depletion was restricted to 5-FU.
To assess the effect of a reduction in RNR activity on the sus-
ceptibility of Mtb to 5-FU, we constructed a conditional knock-
down in nrdF2, which encodes the small subunit of the essential
class Ib RNR (Dawes et al., 2003), using the same promoter
replacement methodology. The nrdF2 Tet-OFF mutant showed
a clear ATc-dependent growth phenotype, consistent with the
essentiality of this gene (Dawes et al., 2003) (Figure 5B). Tran-
scriptional silencing of nrdF2 resulted in an increase in sensitivity
ofMtb to 5-FU comparable with that resulting from thyX silencing
(Figure 5C) without affecting the susceptibility to a range of stan-
dard antituberculars (data not shown). However, the nrdF2 Tet-
OFF mutant was profoundly hypersensitive to the class I RNR
inhibitor, hydroxyurea (HU), as evidenced by the shift in MIC90
from 10 mM in the wild-type and nrdF2-SCO strains to <
30 mM in the nrdF2 Tet-OFF strain (Figure S6).
DISCUSSION
The mechanisms of action, activity modulation, and catabolism
of 5-FU as an anticancer drug have been the subjects of intense
investigation (Longley et al., 2003). Until recently, the primary
target of 5-FU in mammalian cells was thought to be TS.
The identification of a covalent complex between FdUMP,Chemistry & Biology 22,5,10-methylenetetrahydrofolate and TS provided compelling ev-
idence in support of this model, which encouraged the develop-
ment of new anticancer drugs targeted against this enzyme.
However, the therapeutic model implicating TS as the primary
target of 5-FU was called into question by an analysis of the rela-
tionship between TS expression and patient response to 5-FU
treatment (Showalter et al., 2008), which pointed toward the po-
tential importance of alternate metabolites and targets for 5-FU,
such as FUTP and RNA misincorporation (Longley et al., 2003),
and underscored the need for more predictive biomarkers of
therapeutic response to this drug (Bunz, 2008). This notion was
reinforced by studies in yeast, which identified tRNA maturation
as an important target for 5-FU (Gustavsson and Ronne, 2008).
In the present study, we used a combination of postgenomic
and classical biochemical approaches to elucidate the mecha-
nisms of resistance and action of 5-FU in Mtb. The identification
of two distinct mechanisms of resistance involving upp and pyrR
is consistent with an earlier report (Tsukamura, 1979). Our finding
that Upp has a higher specific UPRTase activity than PyrR is
consistent with observations in Bacillus subtilis (Martinussen
et al., 1995) and with structural features of Mtb PyrR that may
limit its activity, such as greater solvent exposure of the sub-
strates binding pocket, the lack of key hydrophobic residues to
stabilize uracil binding for catalysis, the lack of conserved resi-
dues involved in transition state stabilization, and uncertainty
in the location of the catalytic Mg2+ binding site (Kantardjieff
et al., 2005). The dual-resistance mechanism elucidated in Mtb
is also consistent with findings in other bacteria, in whichmultiple
mechanisms have been identified that map to genes in pyrimi-
dine salvage (upp and udk [uridine kinase] in Streptococcus
pneumoniae [Bean and Tomasz, 1973]; upp, thymidine phos-
phorylase [deoA] and thymidine kinase in Lactococcus lactis
[Martinussen and Hammer, 1994]; and upp in B. subtilis [Marti-
nussen et al., 1995]), biosynthesis (pyrR in B. subtilis [Martinus-
sen et al., 1995]), and uptake (pyrP in Lactobacillus plantarum
[Arse`ne-Ploetze et al., 2006]). Although common, mutations in63–75, January 22, 2015 ª2015 Elsevier Ltd All rights reserved 69
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Figure 5. Depletion of ThyX or NrdF2 Con-
fers Moderate Hypersensitivity of Mtb to
5-FU
(A) The effect of ThyX depletion on the suscepti-
bility to 5-FUwas assessed using the thyX Tet-OFF
mutant in a checkerboard assay. The WT (H37Rv)
and thyX-SCO strains were included as controls.
Bacterial viability was assessed by the Alamar Blue
assay. Results are mean ± SD from three inde-
pendent experiments. The numbers in parenthe-
ses denote the concentration of ATc (ng/ml).
Ninety percent inhibition is represented by the
dashed horizontal line.
(B) ATc dose-dependent growth of a conditional
knockdown in nrdF2. Growth of the nrdF2 Tet-OFF
mutant was assessed in 7H9 liquid medium sup-
plemented with the indicated concentrations of
ATc. As expected, growth of the wild-type (H37Rv)
and nrdF2-SCO controls was unaffected by ATc
over the concentration range tested. The numbers
in parentheses denote the concentration of ATc
(ng/ml).
(C) The effect of NrdF2 depletion on 5-FU sus-
ceptibility was determined in a checkerboard
assay using Alamar Blue to monitor bacterial
viability and including WT (H37Rv) and nrdF2-SCO
as controls. Results are mean ± SD from three in-
dependent experiments. The numbers in paren-
theses denote the concentration of ATc (ng/ml).
See also Figure S6.
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L. lactis, L. plantarum, and other bacteria (Arse`ne-Ploetze et al.,
2006) because they are able tometabolize 5-FU to FdUMP via an
alternate route that involves the sequential action of DeoA and
thymidine kinase.
This route, which bypasses the need to produce FUMP, also
limits the level of 5-FU resistance in B. subtilis caused by muta-
tions in pyrR, either alone or in conjunction with mutations in upp
(Martinussen et al., 1995). The absence of this pathway in Mtb
thus exacerbates the impact of loss of Upp function on 5-FU sus-
ceptibility by restricting metabolism via FUMP. However, uracil
supplementation could not rescue the Upp-deficient, 5-FUR
mutant MTBSRM1 from residual 5-FU toxicity, thus implicating
an alternate target or targets for 5-FU whose inhibition is appar-70 Chemistry & Biology 22, 63–75, January 22, 2015 ª2015 Elsevier Ltd All rights reservedently unaffected by PyrR-catalyzed pro-
duction of FUMP. The samemetabolic re-
striction also explains the high level of 5-
FU resistance associated with mutations
in pyrR. In B. subtilis, pyrR mutants resis-
tant to 5-FU were shown to excrete high
amounts of pyrimidines as a result of
overexpression of pyrimidine biosynthetic
genes (Martinussen et al., 1995). We iden-
tified five different nsSNPs in pyrR that
conferred high-level resistance to 5-FU
inMtb. All five pyrR genotypes were asso-
ciated with specific overexpression of
pyr-operon-encoded proteins confirming
that the Leu62Pro, Asp91Asn, Gly125Val,
Arg126Cys, and Leu180Pro mutations alladversely affect the regulator function of PyrR and lead to dysre-
gulated overproduction of UMP, which protects Mtb against
FUMP toxicity. Interestingly, in the one case that was analyzed,
the mutation in PyrR (Asp91Asn) also resulted in transcriptional
upregulation of the pyr operon. Thus, unlike M. smegmatis, in
which PyrR specifically binds RNA to mediate regulation at the
level of translation (Fields and Switzer, 2007), Mtb PyrR appears
to play a dual role in both transcriptional and translational regu-
lation of the pyr operon. However, the apparent transcriptional
upregulation could also be due to an increase in RNA stability.
Mapping of the fivemutations on the structure of Mtb PyrR struc-
ture (Kantardjieff et al., 2005) and other PyrR structures placed
the Gly125 and Arg126 sites in close proximity to the nucleotide
binding site, suggesting that mutations in these residues might
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Leu62 are in close proximity to each other but remote from this
site, whereas Asp91 is remote from this site but proximal to
Arg126 (Figure S7). The molecular basis underlying the defect
in PyrR function is therefore less obvious in these cases.
FUrd and FdUrd showed very poor antimycobacterial activity
arguing against the existence of noncanonical uridine kinase
and thymidine kinase activities in Mtb. However, the 5-FUR mu-
tants of Mtb carrying mutations in upp or pyrR showed cross-
resistance to both compounds, suggesting that these fluoropyr-
imidinesmediate their weak antitubercular activity through 5-FU,
presumably via the action of DeoA in the case of FdUrd, and via
either DeoA or an alternate, noncanonical uridine phosphorylase
in the case FUrd.
An important consequence of the restricted metabolism of 5-
FU via FUMP is that it facilitates 5-FU incorporation into sugar
nucleotides, which inhibit biosynthesis of the mycobacterial
cell wall. Early studies provided evidence for inhibition of cell
wall biosynthesis by 5-FU in E. coli K-12 (Tomasz and Borek,
1962; Tomasz and Borek, 1960) and S. aureus (Rogers and
Perkins, 1960; Stickgold and Neuhaus, 1967). In this study, we
identified fluorinated versions of UDP-Gal, UDP-GlcNAc, and
UDP-MurNAc-pentapeptide in 5-FU-treated Mtb. Several en-
zymes essential for mAGP biosynthesis require these molecules
as substrates. UDP-GlcNAc is a donor of GlcNAc-1-phosphate
for synthesis of decaprenyl-P-P-GlcNAc catalyzed by WecA
(Rv1302), which is the first step in arabinogalactan buildup (Ishi-
zaki et al., 2013; Mikusova´ et al., 1996). Rhamnosyltransferase
WbbL (Rv3265c) uses dTDP-Rha as a donor to attach Rha to de-
caprenyl-P-P-GlcNAc, giving rise to decaprenyl-P-P-GlcNAc-
Rha (Mills et al., 2004), which serves as a carrier for galactan syn-
thesis catalyzed by galactosyltransferases GlfT1 (Rv3782) and
GlfT2 (Rv3808c) (Bela´nova´ et al., 2008). Both of these enzymes
require UDP-Galf. UDP-MurNAc-pentapeptide is the substrate
for translocase I (Rv2156c) producing peptidoglycan precursor
lipid I (decaprenyl-P-P-MurNAc-pentapeptide). In addition,
UDP-GlcNAc donates GlcNAc for MurG (Rv2153c)-catalyzed
synthesis of lipid II (decaprenyl-P-P-MurNAc-[pentapeptide]-
GlcNAc), which is the substrate for peptidoglycan polymerizing
enzymes (Barry et al., 2007). Accumulation of 5-FUDP-Mur-
NAc-pentapeptide upon 5-FU treatment was shown previously
in S. aureus and was suggested to act as a competitive inhibitor
of translocase I (Stickgold and Neuhaus, 1967). Identification of
5-F-UDP-MurNAc-pentapeptide implies that this could also be
the case for mycobacteria. Although we did not investigate the
effects of fluorinated FUDP-sugars on activities of the individual
enzymes mentioned earlier, it is clear that presence of 5-FU in
these molecules interfered with their role to serve as activated
sugar donors for mAGP production, an effect consistent with
reduction of mAGP content and with the upregulation of cell
wall stress-responsive genes.
TB drugs that target cell wall metabolism are known to be
bactericidal (Jackson et al., 2013). Therefore, the inhibition of
cell wall biosynthesis is likely to be a major contributor to the
bactericidal activity of 5-FU. However, 5-FU is also incorporated
into DNA and RNA, with possible bactericidal consequences as
well for Mtb. The upregulation of recA and radA expression in
Mtb cells treated with 5-FU suggests the formation of strand
breaks in DNA containing 5-FU through uracil DNA glycosylaseChemistry & Biology 22,and AP endonuclease action, as observed in cancer cells
(Noordhuis et al., 2004; Yin and Rustum, 1991). However, the
modest induction of these genes by 5-FU in comparison with
classic DNA-damaging agents argues against genotoxicity as
a major contributor to the bactericidal activity of 5-FU. In other
organisms, 5-FU has also been shown to inhibit tRNA modifying
enzymes (Gustavsson and Ronne, 2008), including pseudouri-
dine synthase (Kammen et al., 1988; Samuelsson, 1991) and 5-
methyluridine methyltransferase (Santi and Hardy, 1987). Mtb
has two tRNA pseudouridine synthases, TruA (Rv3455) and
TruB (Rv2793c). Because TruA is essential for growth of Mtb
in vitro (Sassetti et al., 2003), inhibition of its function by fluori-
nated tRNA might have bactericidal consequences for Mtb.
The results of this study thus highlight the difficulties in establish-
ing the relative contributions of different inhibitory mechanisms
to the overall mechanism of action of antimycobacterials that
act via multiple pathways.
The pyrimidine biosynthesis and salvage pathways ofMtb have
been the subject of considerable interest in terms of TB drug
development (reviewed by Villela et al. [2011] and Warner et al.
[2014]). Of the targets identified in these pathways, ThyX has at-
tracted most attention by virtue of its essentiality and unusual
mechanism of action, which distinguishes it from the mammalian
TS (Basta et al., 2012; Fivian-Hughes et al., 2012; Hunter et al.,
2008). FdUMP is a potent inhibitor of both TS enzymes in Mtb:
the nonessential, canonical ThyA and ThyX (Fivian-Hughes
et al., 2012; Hunter et al., 2008). Given the demonstrated utility
of conditional mutants as tools for assessing the target selectivity
of antimycobacterial agents (Abrahams et al., 2012; Kolly et al.,
2014; Kumar et al., 2012; Lechartier et al., 2014; Ollinger et al.,
2012), we used this approach to indirectly ascertain whether
5-FU is metabolized to FdUMP in Mtb by determining the im-
pact of ThyX depletion on 5-FU susceptibility. ThyX depletion
conferred modest hypersensitivity to 5-FU without affecting sus-
ceptibility to drugs that target other cellular processes, suggest-
ing that there is some metabolic flux of 5-FU to FdUMP in Mtb.
However, the extent of sensitization was markedly less than
that observed for cases in which the inhibitor has a primary or
sole target in Mtb (Abrahams et al., 2012; Kolly et al., 2014),
thus arguing against ThyX inhibition as a major contributor to
the mechanism of action of 5-FU. However, the ThyX knock-
downs described here may be useful for other drug discovery ef-
forts focusing on this target (Basta et al., 2012; Ko¨gler et al., 2011).
Conditional depletion of NrdF2, the essential small subunit of
the class Ib RNR, conferred a similar level of hypersensitivity of
Mtb to 5-FU as that conferred by ThyX depletion. In the case
of NrdF2, the hypersensitization could be due to direct inhibition
of RNR activity by FUDP, exacerbation of 5-FU toxicity by
limiting dNTP pools for repair of DNA stand breaks (Yanamoto
et al., 2005), or remodeling of the metabolic flux of 5-FU to favor
the targeting of cell wall synthesis and RNA incorporation at the
expense of DNA incorporation and thymidylate synthesis. The
extreme hypersensitivity of the nrdF2 Tet-OFF mutant to the
RNR inhibitor HU has likewise underscored the potential utility
of this strain in other drug discovery efforts (Nurbo et al., 2013).
Finally, although this and other studies have confirmed that
5-FU and uracil are able to penetrate Mtb, it is unclear whether
this organism engages a specific transport system for uptake
of these (and other) pyrimidines. Nucleobase permeases in63–75, January 22, 2015 ª2015 Elsevier Ltd All rights reserved 71
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NCS1 and NCS2 (http://www.tcdb.org) (Saier et al., 2014). Ho-
mologs belonging to the NCS1 and NCS2 families have been
identified in M. smegmatis (MSMEG_5730 and MSMEG_0564,
respectively) and other mycobacteria but are not present in
Mtb. Therefore, how pyrimidine uptake is mediated in Mtb, and
whether transport might be a limiting factor both in 5-FU efficacy
and the potential mitigation thereof by pyrimidine salvage, are
important questions that are currently under investigation in
our laboratory.
SIGNIFICANCE
Themagnitude of the global health problem of TB, combined
with the emergence and spread of strains of Mtb that are
resistant to first- and second-line drugs, has led to an un-
precedented effort in recent years to develop new TB drugs
with novel mechanisms of action. Phenotypic approaches
which harness the power of postgenomic technologies are
playing a pivotal role in identifying small molecules that
display whole-cell activity against Mtb and can be used as
chemical probes to discover new drug targets and reveal
metabolic vulnerabilities in this formidable human path-
ogen. In this study, we used a combination of chemical
genetics, trace metabolite labeling, macromolecular incor-
poration assays, and protein biochemistry to investigate
the mechanisms of resistance and action of 5-FU, a com-
pound that has been in use for more than five decades as
an anticancer drug and whose antibacterial activity has
been well documented. We show that metabolism of 5-FU
to FUMP constitutes the first and only route of activation
of this prodrug, consistent with deficiencies in the pyrimi-
dine salvage pathway of Mtb. Resistance of Mtb to 5-FU is
mediated either by mutations in upp that abrogate FUMP
production, or bymutations in pyrR that impair the repressor
function of the pyrimidine regulator and result in over-
production of UMP through de novo biosynthesis, which
rescues the cell from the toxic effects of downstream me-
tabolites of 5-FU. These include uracil mimetics that were
shown to act on cell envelope biogenesis, RNA synthesis,
DNA synthesis, and thymidylate synthesis. Althoughmodest
hypersensitization conferred by conditional depletion of the
flavin-dependent TS ThyX implicated ThyX inhibition in the
mechanism of action of 5-FU, the inhibition of mycolyl arabi-
nogalactan peptidoglycan is likely to constitute the principal
mechanism of bactericidal action of this drug.
EXPERIMENTAL PROCEDURES
Bacterial Growth Conditions
The bacterial strains and growth conditions used in this study are described in
Table S4 and in Supplemental Experimental Procedures.
Construction of Plasmids
The plasmids and oligonucleotides used in this study are described in Table S4
and Table S5, and the methods used to construct the plasmids are described
in Supplemental Experimental Procedures.
Construction and Genotypic Confirmation of Mutant Strains
Mutant strains were constructed and genotypically characterized as described
in Supplemental Experimental Procedures.72 Chemistry & Biology 22, 63–75, January 22, 2015 ª2015 ElsevierDrug Susceptibility Testing
Broth microdilution assays for MIC testing and time-kill assays were per-
formed as described in Supplemental Experimental Procedures.
Analysis of Gene Expression by ddPCR
Quantitative gene expression analysis was carried out following extraction of
total RNA from mid-log phase cultures (optical density at 600 nm [OD600] =
0.5) treated with the drug, as indicated, using a FastRNA ProBlue Kit (MP Bio-
medicals) per themanufacturer’s instructions. Two rounds of DNase treatment
of RNA were carried out using Turbo DNase (Ambion), following which 100 ng
DNase-treated RNA was used as template for cDNA synthesis using MMLV
High Performance Reverse Transcriptase (Epicenter). Primers and TaqMan
minor groove binder (MGB) probes (Table S5) were designed using Primer
Express software version 3.0.1. TaqMan MGB probes homologous to the
target gene were labeled with 6-carboxyfluorescein, whereas the reference
gene, sigA, was labeled with 4,7,20-trichloro-7’-phenyl-6-carboxyfluorescein,
thereby facilitating multiplexing of the assay. Primers-probe amplification con-
ditions for duplex PCR were first optimized by gradient PCR. Reaction mix-
tures (20 ml) containing 1 ng of RNA-equivalent cDNA, 1 3 ddPCR Supermix
for probes (Bio-Rad), 500 nM of each primer, and 250 nM of each TaqMan
probe were emulsified with droplet generator oil and partitioned into droplets
using a QX200 Droplet Generator (Bio-Rad). PCR amplification was performed
using a two-step thermocycling protocol (95C for 10 min, 40 cycles at 94C
for 30 s and 57.5C for 60 s, and 98C for 10 min) in a conventional T100 Ther-
mal Cycler (Bio-Rad), following which the droplets were analyzed using a
QX200 Droplet Reader (Bio-Rad). Three technical replicates of each gene
were run for each biological replicate. The absolute number of gene copies
present was determined and normalized to sigA by the QuantaSoft Software
version 1.4.0.99 (Bio-Rad), which was used to analyze the fluorescence data
from each individual well by applying Poisson statistics to the fraction of
endpoint positive reactions (Hindson et al., 2011). For the comparative anal-
ysis, all data points from three biological replicates of each sample were
divided by the mean of the control sample to obtain the fold change relative
to control which was log2 transformed. One-way ANOVA was then performed
across all data points of three biological replicates of the test samples followed
by the Bonferroni multiple-comparisons test to analyze the significance (p
value) using GraphPad Prism version 6.00 for Windows (GraphPad Software).
Western Blot Analysis
Western blot analysis was carried out as described in Supplemental Experi-
mental Procedures.
Isolation of 5-FUR Mutants of Mtb
Mutants of Mtb resistant to 5-FU were isolated as described in Supplemental
Experimental Procedures.
Expression and UPRTase Activity Analysis of Recombinant Mtb Upp
and PyrR
MtbUpp and PyrR were expressed as His-tag recombinants in E. coli, purified,
and tested for UPRTase activity as described in Supplemental Experimental
Procedures.
Radiolabeling and Extraction of Cytosolic Metabolites and Nucleic
Acids
For radiolabeling, Mtb H37Ra was grown to exponential phase in a static cul-
ture in 7H9 (Difco) medium supplemented by 10% ADC and 0.05% Tween at
37C. 5-Fluoro[2-14C]uracil (specific radioactivity 55 mCi/mmol; American Ra-
diolabeled Chemicals) was added to the culture at a concentration of 0.2 mCi/
ml. For the time-course experiment, radiolabeling was started at an OD600 of
0.45, and two 2 ml aliquots of the cell suspension were collected at time inter-
vals of 1, 3, 6, 9, 12, 24, and 48 hr. The sedimented cells were washed twice in
excess ice-cold physiological solution to remove residual 5-F[14C]U from the
media. Cell pellets were resuspended in 100 ml of ddH2O, followed by addition
of 10 ml of concentrated formic acid. The cell suspensions were incubated on
ice for 30 min, with vortexing every 5 min. Cellular debris was removed by
centrifugation at 22,000 3 g for 10 min at 4C; the supernatant was collected
and stored at20C. Nucleic acids were extracted and analyzed as described
in Supplemental Experimental Procedures.Ltd All rights reserved
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PEI Cellulose F (Millipore) plates were used for analysis of radiolabeled cell ex-
tracts. After loading the samples (5–15 ml), the plate was soaked in methanol
for 10 to 20 min to dehydrate the plate and remove contaminating salts. The
plate was then developed in 0.9 M guanidine hydrochloride (Sigma-Aldrich)
(Bochner and Ames, 1982), air dried at room temperature, and exposed to Ko-
dak BioMax MR film at 80C. Cold nucleotide and sugar nucleotide stan-
dards were visualized by UV (l = 254 nm).
Enzymatic Analysis of Radiolabeled Metabolites
Radiolabeled metabolites were enzymatically analyzed as described in Sup-
plemental Experimental Procedures.
Isolation of Cytosolic Metabolites and mAGP from Mtb H37Rv
Mtb H37Rv was grown in 120ml of 7H9media supplemented with OADC to an
OD600 of 0.5, at which point 5-FU was added at a final concentration of 4 mM to
one of the cultures and incubation continued for a further 6 days. Harvested
cells were washed twice with cold physiologic solution and extracted with
5 ml of 10% formic acid for 30 min on ice. After separation of the extract
from the cell residue by centrifugation (3,900 3 g for 3 hr), the procedure
was repeated with additional 5 ml of 10% formic acid, and the combined su-
pernatants were filtered through 0.22 mmfilter. The cell pellets were heat-killed
(80C for 60 min) and lyophilized along with the formic acid extracts. These
were then recovered in 10 ml of ddH2O per 1 mg of dry cell pellet. mAGP
was isolated from approximately 40 mg of control and 5-FU-treated, lyophi-
lized cells according to the method of Bhamidi et al. (2011), with minor modi-
fications, as described in Supplementary Experimental Procedures.
Analysis of Diaminopimelic Acid and Monosaccharide Composition
of mAGP
Approximately 1 mg of mAGP was derivatized according to Bhamidi et al.
(2011) for GC/MS analysis of diaminopimelic acid (DAP) and monosaccharide
content. The details of the procedures are described in Supplemental Exper-
imental Procedures.
HPLC Analysis of Cytosolic Metabolites
HPLC analyses were carried out using a 1200 liquid chromatograph (Agilent
Technologies) equipped with a quaternary pump, autosampler, DAD detector,
and fraction collector. The sampleswere separated on a BioBasic AX anion ex-
change HPLC column (2503 2.1 mm, 5 mm particle size). The separation was
performed using a gradient of 100% solvent A (0.5 mM KH2PO4 [pH 3.2]) to
100% solvent B (0.75 M KH2PO4 [pH 3.2]). Typically, 5 ml of sample was in-
jected for analysis, with a flow rate of 0.35 ml/min, and the total run time was
30 min. The separated compounds were detected at 254 nm. The standards
UMP,UDP, UTP,UDP-GlcNAc, andUDP-Galwere fromSigma, andUDP-Mur-
NAc-pentapeptide and UDP-MurNAc tripeptide (both containing DAP) were
purchased from BaCWAN Synthetic Facility (University of Warwick).
Proteomic Analysis
Mid-log phase cells were washed oncewith PBS and resuspended in PBSwith
protease inhibitor (Complete-mini; Roche), 1mMdithiothreitol (DTT), and 1mM
EDTA and thereafter lysed by 10 to 12 cycles of bead beating for 1 min at
maximum speed with a cooling interval of 5 min using a Ribolyser (MP-Bio).
Lysates were clarified by centrifugation at 15,000 3 g, and the cytoplasmic
protein fractions were precipitated using trichloroacetic acid. Proteins were re-
suspended in 6M urea, and concentrationswere estimated using BCA reagent
(Sigma-Aldrich). Twentymicrograms of denatured protein was reduced and al-
kylated with DTT and iodoacetamide, respectively, and digested with 2 mg of
sequencing grade trypsin (Promega) in 50 mM ammonium bicarbonate with
0.6 M urea at 37C for 16 hr. Reactions were stopped by acidification with
0.1% trifluoroacetic acid, and the released peptides were loaded on activated
C-18 stage tips, prepared in house. Desalted peptides were elutedwith 60% to
80% acetonitrile and resuspended in 0.1% formic acid for MS analysis.
Desalted tryptic digests were separated through nano-C18 reverse phase
chromatography and analyzed by MS-MS. Briefly, 200 ng of peptides were
loaded on an in-house-packed 50 cm capillary column (ID 75 mm, 5 m,
100 A˚) through a trap column (Acclaim-Pepmap-100; Thermo Scientific) with
the help of a nano-LC pump (Dionex-Ultimate 3000 RS-nanoLC) connectedChemistry & Biology 22,in line with Q-Exactive orbitrap (Thermo Scientific). Peptides were eluted
with an increasing gradient of acetonitrile in 0.1% formic acid (2%–25% in
115 min to 35% in further 5 min) at a flow rate of 300 nl min1 and analyzed
by MS. The orbitrap was operated under positive ion mode and switched be-
tween full scan (range 350–1,750 m/z, resolution 70,000) and data-dependent
MS-MS (resolution 17,500) modes using the Xcalibur-2.1 software (Thermo
Scientific). The top 10 ions from every full scan mode were selected for MS-
MS (isolation width 4 m/z) and fragmented by higher-energy C-trap dissocia-
tion and excluded after 30 s.
RawMS files were processed for peptide identification by searching against
the Mtb protein sequence database (http://www.tbdb.org) using MaxQuant
freeware version 1.5.2 (Cox and Mann, 2008). MS-MS spectra for tryptic pep-
tides of length 7 to 30 amino acids with a maximum charge +7, maximum two
sites of miscleavage, and maximum five variable modifications including
methionine oxidation and N-terminal acetylation, with a mass tolerance of
4.5 ppm, were used for unambiguous identification of the individual peptide
sequences from the peptide fragment ion spectra. A false discovery rate of
0.01% was kept throughout the search. A minimum of one unique peptide
was required for unambiguous protein identification. For label-free quantifica-
tion, both unique and razor peptides were considered and intensities of the
tryptic peptides were used by intensity based absolute quantification (iBAQ)
algorithm (Schwanha¨usser et al., 2011) integrated in the MaxQuant software.
The iBAQ intensities of the protein groups were normalized using the total in-
tensity of the LC-MS runs and represented as intensities per bacillus, as esti-
mated from the protein content before trypsin digestion. Two-way ANOVAwas
then performed across all data points of three biological replicates followed by
Bonferroni multiple-comparisons test to analyze the statistical significance (p
value) using GraphPad Prism version 6.00 for Windows. Intensities of proteins
in the 5-FUR mutants and in MTBSRM2::pyrR strain were plotted as a log2 fold
change with respect to the corresponding proteins in H37Rv.
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